Medical therapy can improve the biological properties of the chronically failing heart: A new era in the treatment of heart failure

Circulation

Volumn 94, Issue 9, 1996, Pages 2285-2296

  Eichhorn, Eric J ^a   Bristow, Michael R ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

heart failure; myocardial contraction; remodeling

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL FEATURE; DRUG EFFECT; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029845123     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2285     Document Type: Review

References (156)

1. Braunwald E, Grossman W. Clinical aspects of heart failure. In: Braunwald E, ed. Heart Disease. Philadelphia, Pa: WB Saunders; 1992:444.
2. Ross J, Braunwald E. Studies on Starling's law of the heart: the effects of impeding venous return on performance of the normal and failing human left ventricle. Circulation. 1964;30:719-727.
3. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
4. Packer M, Carver JR, Chesebro JH, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, and the PROMISE investigators. Effect of milrinone on mortality in severe chronic heart failure: the Prospective Randomized Milrinone Survival Evaluation (PROMISE). N Engl J Med. 1991;325:1468-1475.
5. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M, and the PROFILE Investigators and Coordinators. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation. 1993;88(suppl I):I-301. Abstract.
6. Califf RM, Adams KF, Armstrong PW, Darius H, Gheorghiade M, Handberg E, Harrell FE, McKenna WJ, McNulty SE, Schulman K, Soler-Soler J, Swedberg K, Uretsky B, Wheeler WS, Zannad F. Flolan International Randomized Survival Trial Study (FIRST): final results. J Am Coll Cardiol. 1996;27(suppl A): 141 A. Abstract.
7. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA, and the Principal Investigators of the REFLECT Study. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. J Am Coll Cardiol. 1993;22:65-72.
8. Dibianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320:677-683.
9. Packer M, Francis GS, Abrams J, Cobb FR, Eichhorn EJ, Giles TD, Kahl FR, Tandon PK. Oral milrinone increases the risk of sudden death in severe chronic heart failure: the PROMISE Trial. Circulation. 1991;84(suppl II):II-310. Abstract.
10. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. N Engl J Med. 1986;314:290-299.
11. Kessler P, Packer M, Medina N, Yushak M. Long-term hemodynamic and clinical responses to flosequinan, a new once-daily balanced direct-acting vasodilator, in severe heart failure. Circulation. 1986;79(suppl II):II-509. Abstract.
12. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol. 1982;50:320-324.
13. Fouit JM, Tavolaro O, Antony I, Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation. 1988;77:337-344.
14. Ikram H, Fitzpatrick D. Double blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet. 1981;2:490-493.
15. Currie PJ, Kelly KJ, McKenzie A, Harper RW, Lim YL, Federman J, Anderson ST, Pitt A. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol. 1984;3:203-209.
16. Stephen SA. Unwanted effects of propranolol. Am J Cardiol. 1966;18:463-472.
17. Packer M, Lee WH. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. Am J Cardiol. 1986;57:347-348.
18. Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987;106:346-354.
19. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
20. Haber HL, Simek CL, Gimple LW, Bergin JD, Subbiah K, Jayaweera AR, Powers ER, Feldman MD. Why do patients with congestive heart failure tolerate the initiation of β-blocker therapy? Circulation. 1993;88:1610-1619.
21. Francis GS. The relationship of the sympathetic nervous system and the renin-angiotensin-aldosterone system in congestive heart failure. Am Heart J. 1989;118:642-648.
22. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation. 1987;75 (suppl IV):IV-80-IV-92.
23. Mitchell JH, Wallace AG, Skinner NS. Intrinsic effects of heart rate on left ventricular performance. Am J Physiol. 1963;205:41-48.
24. Glower DD, Spratt JA, Snow ND, Kabas JS, Davis JW, Olsen CO, Tyson GS, Sabiston DC, Rankin JS. Linearity of the Frank-Starling relationship in the intact heart: the concept of preload recruitable stroke work. Circulation. 1985;71:994-1009.
25. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
26. Katz A. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med. 1994;121:363-371.
27. 2-adrenergic stimulation in man using atenolol and propranolol. Circulation. 1983;67:1076-1084.
28. Bristow, MR, Abraham WT. Anti-adrenergic effects of angiotensin converting enzyme inhibitors. Eur Heart J. 1995;16:37-41.
29. Malik KU, Nasjletti A. Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries. Circ Res. 1976;38:26-30.
30. Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, Chatterjee K. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol. 1984;54:783-786.
31. Hasking GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephine spillover to plasma in patients with conjestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621.
32. Laragh JH, Angers M, Kelly WG, Lieberman S. Hypotensive agents and pressor substances: the effect of epinephrine, norepinephrine, angiotensin II. and others on the secretory rate of aldosterone in man. JAMA. 1960;174:234-240.
33. Schrier RW, Bichet DG. Osmotic and nonosmotic control of vasopressin release and the pathogenesis of impaired water excretion in adrenal, thyroid, and edematous disorders. J Lab Clin Med. 1981;98:1-15.
34. Bonjour JP, Malvin RL. Stimulation of ADH release by the reninangiotensin system. Am J Physiol. 1970;218:1555-1559.
35. Dzau VJ. Local contractile and growth modulators in the myocardium. Clin Cardiol. 1993;16:II-5-II-9.
36. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvany MJ, Strauer BE. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3-16.
37. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
38. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro: roles of phospholipid-derived second messengers. Circ Res. 1993;73:424-438.
39. Simpson P, McGrath A. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1-adrenergic response. J Clin Invest. 1983;72:732-737.
40. Sen S, Tarazi RC. Regression of myocardial hypertrophy and influence of the adrenergic system. Am J Physiol. 1983;244:H97-H101.
41. Edwards BS, Zimmerran RS, Schwab TR, Heublein DM, Burnett JC. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988;62:191-195.
42. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med. 1984;310:347-352.
43. Hasenfuss G, Holubarsch C, Heiss HW, Meinertz T, Bonzel T, Wais U, Lehmann M, Just H. Myocardial energetics in patients with dilated cardiomyopathy: influence of nitroprusside and enoximone. Circulation. 1989;80:51-64.
44. Nelson RR, Gobel FL, Jorgensen CR, Wang K, Wang Y, Taylor HL. Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise. Circulation. 1974;50:1179-1189.
45. Sabbah HN, Sharov VG, Cook JM, Shimoyama H, Lesch M. Accumulation of collagen in the cardiac interstitium of dogs with chronic heart failure is associated with decreased capillary density and increased oxygen diffusion distance. J Am Coll Cardiol. 1995;25:222A. Abstract.
46. Shimoyaina H, Sabbah HN, Sharov VG, Cook J, Lesch M, Goldstein S. Accumulation of interstitial collagen in the failing left ventricular myocardium is associated with increased anaerobic metabolism among affected cardiomyocytes. J Am Coll Cardiol. 1994;23:98A. Abstract.
47. Parodi O, DeMaria R, Oltrona L, Testa R, Sambuceti G, Roghi A, Merli M, Belingheri L, Accinni R, Spinelli F, Pellegrini A, Baroldi G. Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation. Circulation. 1993;88:509-522.
48. Anversa P, Capasso JM. Cardiac hypertrophy and ventricular remodeling. Lab Invest. 1991;64:441-445.
49. Katz A. Cellular mechanisms in congestive heart failure. Am J Cardiol. 1988;62:3A-8A.
50. Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV. Histologic and biochemical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol. 1987;9:734-742.
51. Furchgott RF, Lee KS. High energy phosphates and the force of contraction of cardiac muscle. Circulation. 1961;24:416-428.
52. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
53. Raynolds MV, Bush EW, Taft CS, Roden RA, Bristow MR. Altered gene expression of several rate limiting enzymes in fatty acid oxidation and glycolysis in the failing human heart. Circulation. 1994;90(suppl I):I-209. Abstract.
54. Kjekshus JK, Mjos OD. Effect on inhibition of lipolysis on myocardial oxygen consumption in the presence of isoproterenol. J Clin Invest. 1972;51:1767-1776.
55. Simonsen S, Kjekshus JK. The effect of free fatty acids on myocardial oxygen consumption during atrial pacing and catecholaminc infusion in man. Circulation. 1978;58:484-491.
56. Haft JI. Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis. 1974;17:73-85.
57. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
58. Henegar JR, Brower GL, Kabour A, Janicki JS. Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Am J Physiol. 1995;269:H1564-H1569.
59. Gavras H, Kremer D, Brown JJ, Gray B, Lever AF, MacAdam RF, Medina A, Morton JJ, Robertson JIS. Angiotensin- and norepinephrine-induced myocardial lesions; experimental and clinical studies in rabbits and man. Am Heart J. 1975;89:321-332.
60. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-1195.
61. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M. Alterations in sarcoplasmic reticulum gene expression in human heart failure. Circ Res. 1993;72:463-469.
62. Cory CR, McCutcheon LJ, O'Grady M, Pang AW, Geiger JD, O' Brien J. Compensatory downregulation of myocardial Ca channel in SR from dogs with heart failure. Am J Physiol. 1993;264:H926-H937.
63. Schwartz K, Carrier L, Mercadier J-J, Lompre A-M, Boheler KR. Molecular phenotype of the hypertrophied and failing myocardium. Circulation. 1993;87(suppl VII):VII-5-VII-10.
64. Schwartz K, Boheler KR, DeLaBastie D, Lompre A-M, Mercadier J-J. Switches in cardiac muscle gene expression as a result of pressure and volume overload. Am J Physiol. 1992;262:R364-R369.
65. Abraham WT, Minobe W, Feldman AM, Bristow MR. Assessment of gene expression in endomyocardial biopsy specimens from failing and nonfailing human hearts. J Invest Med. 1995;43(suppl 2): 316A. Abstract.
66. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem. 1990;265:20555-20562.
67. Takemura G, Fujiwra H, Horike K, Mukoyama M, Saito Y, Nakao K, Matsuda M, Kawamura A, Ishida M, Kida M, Uegaito T, Tanaka M, Matsumori A, Fujiwara Y, Fujiwara T, Imura H, Kawai C. Ventricular expression of atrial natriuretic polypeptide and its relations with hemodynamics and histology in dilated human hearts. Circulation. 1989;80:1137-1147.
68. Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, Bristow MR. Selective gene expression in failing human heart. Circulation. 1991:83:1866-1872.
69. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
70. 1-receptor down-regulation in heart failure. Circ Res. 1986;59:297-309.
71. 1 receptor mRNA abundance in the failing human heart. J Clin Invest. 1993;92:2737-2745.
72. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993;71:12C-22C.
73. White M, Wiechmann RJ, Roden RL, Hagan MB, Wollmering MM, Port JD, Hammond E, Abraham WT, Wolfel EE, Lindenfeld J, Fullerton D, Brislow MR. Cardiac β-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury: evidence for catecholamine-mediated myocardial damage. Circulation. 1995;92:2183-2189.
74. Imperato-McGinley J, Gautier T, Ehlers K, Zullo MA, Goldstein DS, Vaughan ED Jr. Reversibility of catecholamine-induced dilated cardtomyopathy in a child with a pheochromocytoma. N Engl J Med. 1987;316:793-797.
75. Packer M, Medina N, Yushak N. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation. 1984;70:1038-1047.
76. Chesebro JH, Browne KF, Fenster PE, Garland WT, Konstam MA. The hemodynamic effects of chronic oral milrinone therapy: a multicenter controlled trial. J Am Coll Cardiol. 1988;11:144A. Abstract.
77. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Sonnenblick EH, Olivetti G, Anversa P. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol. 1995;27:291-305.
78. Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W, Olivetti G, Hintze TH, Anversa P. The cellular basis of pacing-induced dilated cardiomyopathy. Circulation. 1995;92:2306-2317.
79. Searle J, Kerr JF, Bishop CJ. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol Annu. 1982;17:229-259.
80. Valante M, Calabrese F, Baliello E, Basso C, Angelini A, Thiene G. Programmed myocardial cell death (apoptosis) in cardiomyopathies. J Am Coll Cardiol. In press.
81. Nadal-Ginard B. Commitment, fusion, and biochemical differentiation of a myogenic cell line in the absence of DNA synthesis. Cell. 1978;15:855-864.
82. Olson EN. Regulation of muscle transcription by the MyoD family: the heart of the matter. Circ Res. 1993;72:1-6.
83. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van-Bilsen M, O'Brien TX, Evans SM. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol. 1993;55:77-95.
84. Gu W, Schneider JW, Condorelli G, Kaushal S, Mahdavi V, Nadal-Ginard B. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell. 1993;72:309-324.
85. Raynolds M, Blain-Nelson P, Roden R, Bohlmeyer T, Bristow M. Expression of the tumor supressor p53 is increased in the failing myocardium. Keystone Symposium, Molecular Biology of the Cardiovascular System. In press.
86. Raynolds M, Peacock SJ, Roden RL. Induction of the tumor suppressor gene p53 in cardiac tissue may be mediated by angiotensin II. FASEB J. 1995;9:A1281. Abstract.
87. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
88. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor α and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
89. Wyllie AH. Apoptosis: death gets a brake. Nature. 1994;369:272-273.
90. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor a. Nature. 1989;337:661-663.
91. Westwick JK, Weitzel C, Minden A, Karin M, Brenner D. Tumor necrosis factor α stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J Biol Chem. 1994;269:26396-26401.
92. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 1993;74:845-853.
93. Erlebacher JA, Weiss JL, Eaton LW, Kallman C, Weisfeldt ML, Bulkley BH. Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. Am J Cardiol. 1982;49:1120-1126.
94. Sabbah HN, Goldstein S. Ventricular remodeling: consequences and therapy. Eur Heart J. 1993;14(suppl C):24-29.
95. Conn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation. 1995;91:2504-2507.
96. Douglas PS, Morrow R, Ioli A, Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1989;13:311-315.
97. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol. 1992;20:1594-1598.
98. Lamas GA, Vaughan DE, Parisi AF, Pfeffer MA. Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. Am J Cardiol. 1989;63:1167-1173.
99. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
100. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res. 1993;73:413-423.
101. Komuro I, Kaida T, Shibazaki Y, Kurabayashi M, Katoh Y, Hoh E, Takaku F, Yazaki Y. Stretching cardiac myocytes stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes: possible role of protein kinase C activation. J Biol Chem. 1991;266:1265-1268.
102. 1]Angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol. 1990;258:H806-H813.
103. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens, 1989;11:1325-1350.
104. Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 1990;259:H324-H332.
105. Beinlich CJ, White GJ, Baker KM, Morgan HE. Angiotensin II and left ventricular growth in newborn pig heart. J Mol Cell Cardiol. 1991;23:1031-1038.
106. Parker TG, Packer SE, Schneider MD. Peptide growth factors can provoke 'fetal' contractile protein gene expression in rat cardiac myocytes. J Clin Invest. 1990;85:507-514.
107. MacLellan WR, Brand T, Schneider MD. Transforming growth factor-β in cardiac ontogeny and adaptation. Circ Res. 1993;73:783-791.
108. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 1994;89:2852-2859.
109. McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol. 1994;24:1762-1768.
110. Bishopric NH, Sato B, Webster KA. β-Adrenergic regulation of a myocardial actin gene via a cyclic AMP-independent pathway. J Biol Chem. 1992;267:20932-20936.
111. Mann DL, Young JB. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest. 1994;105:897-904.
112. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest. 1992;90:389-398.
113. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh S-M, Darbonne WC, Knutzon DS, Yen R, Chien KR, Baker JB, Wood WI. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci U S A. 1995;92:1142-1146.
114. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, Cooper G, Carabello BA. Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest. 1994;93:2639-2648.
115. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation. 1995;92:2540-2549.
116. Schwinger RHG, Bohm M, Koch A, Schmidt U, Morano I, Eissner H-J, Uberfuhr P, Reichart B, Erdmann E. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res. 1994;74:959-969.
117. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:831-836.
118. Cintron C, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation. 1993;87(suppl VI):VM7-VI-23.
119. Glass MG, Fuleihan F, Hajjar RJ, Gwathmey JK. Negative Treppe in dilated cardiomyopathy: role of abnormal calcium handling. Circulation. 1993;88(suppl I):I-87. Abstract.
120. Fuleihan F, Matsumori A, Gwathmey JK. Effects of carteolol, a β-blocker, on mortality and left ventricular heart function in dilated cardiomyopathy. Circulation. 1993;88(suppl I):I-38. Abstract.
121. Glass MG, Reis I, Cory CR, O'Brien PJ, Gwathmey JK. Reversal of the negative Treppe with β-blockers: role of sarcoplasmic reticulum function and myocardial energetics. Circulation. 1993;88 (suppl I):I-526. Abstract.
122. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85:1743-1750.
123. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88:223-229.
124. Metra M, Nardi M, Giubbini R, DeiCas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
125. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cordial. 1995;25:1225-1231.
126. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
127. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P. Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 1993;21:1094-1100.
128. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995;92:212-218.
129. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
130. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med. 1996;334:1349-1355.
131. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. In press.
132. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
133. Eichhorn EJ. Do β-blockers have a role in patients with congestive heart failure? Cardiol Clin. 1994;12:133-142.
134. Eichhorn EJ, Hjalmarson Å, β-Blocker treatment for chronic heart failure: the frog prince. Circulation. 1994;90:2153-2156.
135. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994;23:814-821.
136. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, Willard JE, Grayburn PA. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. 1990;82:473-483.
137. Wood MA, Hess ML. Review: Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. Am J Med Sci. 1989;297:105-113.
138. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995;16(suppl F):20-31.
139. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim-Barker A, Powell JR, Koster WH. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation. 1995;92:562-578.
140. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 1985;57:84-95.
141. Pfeffer MA, Pfeffer JM. Ventricular enlargement and reduced survival after myocardial infarction. Circulation. 1987;75(suppl IV): IV-93-IV-97.
142. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
143. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
144. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BB, Geltman EM, Goldman S, Flaker GC, Klein M, Lames GR, Packer M, Rouleau J, Roubav JL, Rutherford J, Wertheimer J, Hawkins M, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-677.
145. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80-86.
146. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cordial 1992;19:1136-1144.
147. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991;2: 872-876.
148. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation, 1992;86:431-438.
149. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B, for the SOLVD Investigators. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD Echocardiography Substudy. Circulation. 1995;91:2573-2581.
150. Doherty NE, Seelos KG, Suzuki J-I, Caputo GR, O'Sullivan M, Sobol SM, Cavero P, Chatterjee K, Parmley WW, Higgins CB. Application of cine nuclear magnetic resonance imaging for sequential evaluation of response to angiotensin-converting enzyme inhibitor therapy in dilated cardiomyopathy. J Am Coll Cardiol. 1992;19:1294-302.
151. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation. 1993;88:472-480.
152. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Circulation. 1993;87(suppl VI):VI-40-VI-48.
153. Eichhorn EJ, McGhie AI, Bedotto JB, Corbett JR, Malloy CR, Hatfield BA, Deitchman D, Willard JE, Grayburn PA. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol. 1991;67:67-73.
154. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiol Pharm. 1990,15:959-967.
155. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1995:15(suppl S/B).
156. The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol. 1995;75:1220-1223.